Merck Sharp + Dohme Corp.

Schering Corporation

Mochida Paraceuticals Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

Alan W Hruza

Paul Reichert

Scott D Edmondson

Vincent Stewart Madison

Amjad Ali

Ying-Duo Gao

Santhosh Francis Neelamkavil

Sung-Sau So

M Arshad Siddiqui

Gerald Wayne Shipps, Jr

Tattanahalli L Nagabhushan

Zhuyan Guo

Rongze Kuang

Yongqi Deng

Thierry Olivier Fischmann

Anthony K Ogawa

Wanying Sun

Eric Mertz

Weiguo Liu

Neng-Yang Shih

Ronald J Doll

Jared N Cumming

Alan B Cooper

Joseph Michael Kelly

Wen-Lian Wu

Hong Liu

Shawn P Walsh

Derun Li

Li Xiao

Charles A Lesburg

Brandon Mitsuo Taoka

Haiqun Tang

Brian Alexander McKittrick

Janeta Popovici-Muller

Liangqin Guo

Sunil Paliwal

Harold B Wood

John S Debenham

Dongfang Meng

Peter Orth

Bing Li

Tong Wang

Remond Moningka

Zahid Hussain

Charles W McNemar

Brian M Beyer

Jagdish A Desai

Kevin D Dykstra

Robert Sun

Shahriar Shane Taremi

James J-s Wang

Richard N Ingram

Wolfgang Seghezzi

Hugh Y Zhu

Andrew Joseph Prongay

Stephen Tindall

Yang Nan

Jiafang He

Thomas E Hesson

Rudrajit Mal

Youhao Dong

Andreas Verras

Jessie M English

Lata Ramanathan

Catherine Smith

Xiaolei Gao

Ashwin Umesh Rao

John P Caldwell

Hon-Chung Tsui

Linda Brockunier

Lianyun Zhao

Jayaram R Tagat

Yi-Heng Chen

Rumin Zhang

Nancy J Kevin

Jacqueline D Hicks

Lan Wei

Heping Wu

William T Windsor

Jose S Duca

Dexi Yang

Ahmed Abdi Samatar

Sobhana Babu Boga

Ting Zhang

Mehul F Patel

Patrick J Curran

Nagamani Nagabhushan

Edward C Sherer

Liang Zhu

Yi Zang

Gerald W Shipps

Tianying Jian

Mary Ann Caplen

Claire Lankin

Abdul-Basit Alhassan

David Parry

Todd W Mayhood

Azim Alan Celebi

Emma M Lees

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease. 

Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Factor IXa crystals, related complexes and methods

This application covers a novel PEGylated interferon and a novel crystalline form of interferon which are useful, inter alia, for detailed structural analysis of interferon as well as treatment and prevention of viral infections and hyperproliferative diseases such as leukemia.

Crystal of human interferon alpha 2B in complex with zinc

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Compounds that are ERK inhibitors

Growing community of inventors

Hakettstown, NJ, United States of America

Alan W Hruza